FDA Approves New Option in Obesity - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

  • By

  • Kathryn Wighton

  • February 23, 2026

  • 3 min

Share

  • 1

    The FDA approved the Allurion Gastric Balloon System, a swallowable device for obesity treatment without surgery or anesthesia.

  • 2

    The device is intended for adults aged 22 to 65 with obesity who have previously failed weight loss attempts.

  • 3

    The balloon remains in the stomach for about 4 months, promoting satiety and reducing caloric intake.

  • 4

    The Allurion Smart Capsule offers a safe alternative to glucagon-like peptide-1s and bariatric surgery.

  • 5

    In commercial settings outside the US, the device has shown an average total body weight loss of 14%.

Original Source(s)

FDA Approves New Option in Obesity

  • by Kathryn Wighton

  • February 23, 2026

Related Content

Case Report: ACTH-independent Cushing’s syndrome caused by isolated micronodular adrenal disease in a 23-month-old girl

Application of Just-in-Time Adaptive Interventions in Dietary Health Management: Systematic Review

Association of the sdLDL-C/lbLDL-C ratio with heart failure beyond conventional LDL-C levels: a cross-sectional study